Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: Multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy

Diabetic Medicine

Volumn 29, Issue 12, 2012, Pages 1529-1533

  Hotta, N ^a   Kawamori, R ^b   Fukuda, M ^c   Shigeta, Y ^d  

^a CHUBU ROSAI HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA POLICE HOSPITAL   (Japan)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; EPALRESTAT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DISEASE COURSE; DISEASE SEVERITY; ENZYME INHIBITION; HUMAN; JAPANESE; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALDEHYDE REDUCTASE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; COST-BENEFIT ANALYSIS; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; ENZYME INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEURAL CONDUCTION; RHODANINE; SEVERITY OF ILLNESS INDEX; THIAZOLIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84869108235     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03684.x     Document Type: Article

References (31)

1. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-2293.
2. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34(Suppl 1): S11-S61.
3. Yagihashi S, Mizukami H, Sugimoto K. Mechanism of diabetic neuropathy: Where are we now and where to go?J Diabetes Invest 2011; 2: 18-32.
4. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-824.
5. Tesfaye S, Chaturvedi N, Eaton SEM, Ward JD, Manes C, Ionescu-Tirgoviste C et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-350.
6. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, Shichiri M et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 2006; 29: 1538-1544.
7. Hotta N, Kawamori R, Atsumi Y, Baba M, Kishikawa H, Nakamura J et al. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. Diabet Med 2008; 25: 818-825.
8. Hotta N. Is there a place for inhibition of transforming growth factor-β and the polyol pathway in therapy for diabetic retinopathy?J Diabetes Invest 2010; 1: 134-136.
9. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 2010; 1: 212-228.
10. Nebuchennykh M, Løseth S, Lindal S, Mellgren SI. The value of skin biopsy with recording of intraepidermal nerve fiber density and quantitative sensory testing in the assessment of small fiber involvement in patients with different causes of polyneuropathy. J Neurol 2009; 256: 1067-1075.
11. Davis MD, Myers FL, Bresnick GH, Venecia G. Natural evolution. In: L'Esperance FA Jr, ed. Current Diagnosis and Management of Chorioretinal Diseases. St Louis: CV Mosby, 1977: 179-184.
12. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH et al. Diabetic nephropathy. Diabetes Care 2003; 26(Suppl 1): S94-S98.
13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
14. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-389.
15. Nathan DM, Cleary PA, Backlund JYC, Genuth SM, Lachin JM, Orchard TJ et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
16. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
17. Gabbay KH. The sorbitol pathway and the complications of diabetes. N Engl J Med 1973; 288: 831-836.
18. Malik RA. Current and future strategies for the management of diabetic neuropathy. Treat Endocrinol 2003; 2: 389-400.
19. Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets 2008; 9: 14-36.
20. Schemmel KE, Padiyara RS, D'Souza JJ. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications 2010; 24: 354-360.
21. Tesfaye S. Recent advances in the management of diabetic distal symmetrical polyneuropathy. J Diabetes Invest 2011; 2: 33-42.
22. Barr ELM, Wong TY, Tapp RJ, Harper CA, Zimmet PZ, Atkins R et al. Is peripheral neuropathy associated with retinopathy and albuminuria in individuals with impaired glucose metabolism? The 1999-2000 AusDiab. Diabetes Care 2006; 29: 1114-1116.
23. Kärvestedt L, Mårtensson E, Grill V, Elofsson S, von Wendt G, Hamsten A et al. Peripheral sensory neuropathy associates with micro- or macroangiopathy: results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care 2009; 32: 317-322.
24. Charles M, Soedamah-Muthu SS, Tesfaye S, Fuller JH, Arezzo JC, Chaturvedi N. et al. Low peripheral nerve conduction velocities and amplitudes are strongly related to diabetic microvascular complications in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2010; 33: 2648-2653.
25. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866.
26. Clarke M, Dodson PM. PKC inhibition and diabetic microvascular complications. Best Pract Res Clin Endocrinol Metab 2007; 21: 573-586.
27. Noh H, King GL. The role of protein kinase C activation in diabetic nephropathy. Kidney Int 2007; 72: S49-S53.
28. Nakamura J, Kasuya Y, Hamada Y, Nakashima E, Naruse K, Yasuda Y et al. Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity. Diabetologia 2001; 44: 480-487.
29. Yasunari K, Kohno M, Kano H, Minami M, Yoshikawa J. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose. Hypertension 2000; 35: 1092-1098.
30. Naruse K, Nakamura J, Hamada Y, Nakayama M, Chaya S, Komori T et al. Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes. Exp Eye Res 2000; 71: 309-315.
31. Gerhardinger C, Dagher Z, Sebastiani P, Park YS, Lorenzi M. The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes 2009; 58: 1659-1667.